aTyr Pharma, Inc. (NASDAQ:LIFE) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on Saturday.

Several other equities research analysts also recently weighed in on LIFE. BMO Capital Markets set a $4.00 target price on shares of aTyr Pharma and gave the company a “hold” rating in a research note on Saturday, March 18th. J P Morgan Chase & Co restated a “hold” rating on shares of aTyr Pharma in a research note on Saturday, March 18th. Finally, Citigroup Inc. raised their target price on shares of aTyr Pharma from $3.00 to $4.00 and gave the company a “neutral” rating in a research note on Monday, March 20th. Five research analysts have rated the stock with a hold rating, The stock presently has a consensus rating of “Hold” and a consensus target price of $3.71.

aTyr Pharma (LIFE) traded up 4.48% during trading on Friday, hitting $3.50. 11,133 shares of the stock traded hands. The firm has a 50-day moving average price of $3.46 and a 200 day moving average price of $3.22. The firm’s market cap is $83.32 million. aTyr Pharma has a 12 month low of $2.10 and a 12 month high of $4.45.

aTyr Pharma (NASDAQ:LIFE) last released its quarterly earnings data on Thursday, May 11th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.50) by $0.06. On average, equities analysts forecast that aTyr Pharma will post ($2.18) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at

An institutional investor recently raised its position in aTyr Pharma stock. Renaissance Technologies LLC boosted its stake in shares of aTyr Pharma, Inc. (NASDAQ:LIFE) by 1.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 38,800 shares of the biotechnology company’s stock after buying an additional 700 shares during the period. Renaissance Technologies LLC owned 0.16% of aTyr Pharma worth $136,000 as of its most recent SEC filing. 47.03% of the stock is currently owned by institutional investors.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with's FREE daily email newsletter.